Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition

On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars and the feasibility of switching to them.

Show notes

1. FDA Approves High-Concentration Cyltezo

2. Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars

3. DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use

4. Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD

5. New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching

6. Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD

7. Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings

8. Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar

9. Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment